Compounds > almagate
Page last updated: 2024-08-25

almagate and Infectious Endophthalmitis

almagate has been researched along with Infectious Endophthalmitis in 20 studies

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (30.00)29.6817
2010's14 (70.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ambresin, A; Becker, M; Casparis, H; Eich, G; Graf, N; Mantel, I; Michels, S; Wolfensberger, TJ1
Agrawal, S; Christoforidis, JB; Joshi, M1
Albini, TA; Berrocal, AM; Davis, JL; Dubovy, SR; Flynn, HW; Fortun, JA; Gregori, NZ; Kovach, JL; Moshfeghi, AA; Rosenfeld, PJ; Schwartz, SG; Smiddy, WE; Vaziri, K1
Becker, M; Brynskov, T; Freiberg, FJ; Michels, S; Munk, MR; Sørensen, TL; Wirth, MA; Wolf, S1
Angulo Bocco, MC; Coscas, G; Glacet-Bernard, A; Soubrane, G; Zourdani, A1
Bakri, SJ; Diago, T; Edwards, AO; McCannel, CA; Pach, JM; Pulido, JS1
Castellarin, AA; Driscoll, S; Halperin, LS; Hassan, TS; Klein, KS; Prenner, JL; Roth, D; Walsh, MK1
Anderson, NG; Inman, ZD1
McCannel, CA1
Acquah, K; Day, S; Grossman, DS; Lee, PP; Mruthyunjaya, P; Sloan, FA1
Inoue, M; Kadonosono, K; Kinoshita, S; Kobayakawa, S; Komori, H; Matsushima, H; Senoo, T; Sotozono, C; Suda, Y; Tanaka, K; Tochikubo, T1
Albini, TA; Berrocal, AM; Davis, JL; Dubovy, SR; Flynn, HW; Kovach, JL; Lalwani, GA; Lee, WH; Moshfeghi, AA; Murray, TG; Puliafito, CA; Rosenfeld, PJ; Schwartz, SG; Smiddy, WE1
Brown, DM; Chen, E; Cox, J; Lin, MY1
Grabska-Liberek, I; Jamrozy-Witkowska, A; Jankowska-Lech, I; Kowalska, K; Nowosielska, A; Terelak-Borys, B1
Bodaghi, B; Cochereau, I; Dumarcet, N; Goebel, F; Hajjar, J; Korobelnik, JF1
Fujita, K; Hattori, T; Mori, R; Nakashizuka, H; Shimada, H; Yuzawa, M1
Chen, TC; Englander, M; Kim, IK; Miller, JW; Paschalis, EI1
Meyer, CH1
Heimann, H; Meyer, CH; Ziemssen, F1
Cooney, M; Freund, KB; Klancnik, J; Kotsolis, A; Pilli, S; Slakter, J; Sorenson, J; Spaide, RF1

Reviews

3 review(s) available for almagate and Infectious Endophthalmitis

ArticleYear
Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy.
    Mediators of inflammation, 2013, Volume: 2013

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Humans; Infant, Newborn; Inflammation; Intravitreal Injections; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Diseases; Risk; Vascular Endothelial Growth Factor A; Vitreous Body

2013
Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies.
    Retina (Philadelphia, Pa.), 2011, Volume: 31, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bacteria; Endophthalmitis; Eye Infections, Bacterial; Humans; Incidence; Intravitreal Injections; Ranibizumab; Vascular Endothelial Growth Factor A

2011
[Intravitreal injection. Monitoring to avoid postoperative complications].
    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2008, Volume: 105, Issue:2

    Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cataract; Clinical Trials, Phase III as Topic; Endophthalmitis; Eye Hemorrhage; Female; Fetus; Hallucinations; Humans; Injections; Intraocular Pressure; Macular Degeneration; Mice; Paracentesis; Postoperative Complications; Pregnancy; Rabbits; Randomized Controlled Trials as Topic; Ranibizumab; Retinal Detachment; Uveitis; Vascular Endothelial Growth Factor A; Vitreous Body

2008

Other Studies

17 other study(ies) available for almagate and Infectious Endophthalmitis

ArticleYear
Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study.
    Retina (Philadelphia, Pa.), 2014, Volume: 34, Issue:1

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Female; Humans; Incidence; Intravitreal Injections; Operating Rooms; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Risk Factors; Switzerland; Vascular Endothelial Growth Factor A

2014
Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment.
    Ophthalmic surgery, lasers & imaging retina, 2015, Volume: 46, Issue:6

    Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Eye Infections, Bacterial; Florida; Humans; Incidence; Intravitreal Injections; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Diseases; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity

2015
LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study.
    Retina (Philadelphia, Pa.), 2017, Volume: 37, Issue:12

    Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Denmark; Endophthalmitis; Equipment Contamination; Eye Infections, Bacterial; Follow-Up Studies; Humans; Incidence; Intravitreal Injections; Operating Rooms; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Risk Factors; Switzerland; Time Factors; Vascular Endothelial Growth Factor A; Wet Macular Degeneration

2017
[Intravitreous injection: retrospective study on 2028 injections and their side effects].
    Journal francais d'ophtalmologie, 2008, Volume: 31, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Cataract; Diabetic Retinopathy; Endophthalmitis; Epiretinal Membrane; Humans; Injections; Macular Degeneration; Macular Edema; Ocular Hypertension; Ranibizumab; Retinal Detachment; Retinal Perforations; Retinal Vein Occlusion; Retrospective Studies; Risk Assessment; Triamcinolone Acetonide; Vitreous Body; Vitreous Hemorrhage

2008
Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
    Retina (Philadelphia, Pa.), 2009, Volume: 29, Issue:5

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Ceftazidime; Drug Therapy, Combination; Endophthalmitis; Eye Infections; Female; Humans; Injections; Male; Ranibizumab; Retrospective Studies; Risk Factors; Staphylococcal Infections; Vancomycin; Vitreous Body

2009
Endophthalmitis after anti-VEGF injections.
    Ophthalmology, 2009, Volume: 116, Issue:6

    Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cohort Studies; Drug Therapy, Combination; Endophthalmitis; Humans; Injections; Macular Degeneration; Ranibizumab; Risk Factors; Vascular Endothelial Growth Factor A; Vitreous Body

2009
Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia.
    Retina (Philadelphia, Pa.), 2011, Volume: 31, Issue:4

    Topics: Anesthesia, Local; Anesthetics, Local; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Eye Infections, Bacterial; Humans; Incidence; Intravitreal Injections; Lidocaine; Ranibizumab; Retrospective Studies; Time Factors; Vascular Endothelial Growth Factor A; Visual Acuity

2011
Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
    American journal of ophthalmology, 2011, Volume: 152, Issue:2

    Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Case-Control Studies; Endophthalmitis; Eye Diseases; Female; Follow-Up Studies; Health Services Research; Humans; Incidence; Intravitreal Injections; Macular Degeneration; Male; Medicare Part B; Proportional Hazards Models; Ranibizumab; Retinal Detachment; Retinal Perforations; Retrospective Studies; United States; Uveitis; Vascular Endothelial Growth Factor A; Vitreous Hemorrhage

2011
Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
    Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2011, Volume: 226, Issue:3

    Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Aqueous Humor; Bevacizumab; Endophthalmitis; Enterococcus faecalis; Eye Infections, Bacterial; Gram-Positive Bacterial Infections; Humans; Incidence; Intravitreal Injections; Japan; Middle Aged; Postoperative Complications; Ranibizumab; Retrospective Studies; Streptococcal Infections; Streptococcus oralis; Vascular Endothelial Growth Factor A; Vitreous Body

2011
Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center.
    Retina (Philadelphia, Pa.), 2011, Volume: 31, Issue:4

    Topics: Academic Medical Centers; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Aqueous Humor; Bacteria; Bevacizumab; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Intravitreal Injections; Macular Degeneration; Male; Middle Aged; Ranibizumab; Referral and Consultation; Retrospective Studies; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body

2011
Endophthalmitis after intravitreal injection: the importance of viridans streptococci.
    Retina (Philadelphia, Pa.), 2011, Volume: 31, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Eye Infections, Bacterial; Female; Glucocorticoids; Humans; Incidence; Intravitreal Injections; Male; Middle Aged; Ranibizumab; Retinal Diseases; Retrospective Studies; Risk Factors; Streptococcal Infections; Triamcinolone Acetonide; Viridans Streptococci; Visual Acuity; Vitreous Body

2011
[Complications of intravitreal injections--own experience].
    Klinika oczna, 2011, Volume: 113, Issue:4-6

    Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Conjunctival Diseases; Diabetic Retinopathy; Endophthalmitis; Eye Diseases; Eye Hemorrhage; Female; Follow-Up Studies; Glucocorticoids; Humans; Inflammation; Intravitreal Injections; Iris Diseases; Macular Degeneration; Macular Edema; Male; Middle Aged; Ocular Hypertension; Poland; Ranibizumab; Retinal Diseases; Retinal Vein Occlusion; Retrospective Studies; Risk Factors; Triamcinolone Acetonide; Visual Acuity

2011
[Intravitreal injections: AFSSAPS guide to good practice].
    Journal francais d'ophtalmologie, 2012, Volume: 35, Issue:1

    Topics: Aptamers, Nucleotide; Diabetic Retinopathy; Endophthalmitis; France; Humans; Intravitreal Injections; Macular Degeneration; Ophthalmologic Surgical Procedures; Postoperative Complications; Practice Guidelines as Topic; Retinal Diseases; Retinal Vein Occlusion; Societies, Medical

2012
Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2013, Volume: 251, Issue:8

    Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Conjunctiva; Endophthalmitis; Eye Infections, Bacterial; Humans; Intravitreal Injections; Levofloxacin; Masks; Povidone-Iodine; Ranibizumab; Retrospective Studies; Therapeutic Irrigation; Vascular Endothelial Growth Factor A

2013
Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.
    The British journal of ophthalmology, 2013, Volume: 97, Issue:4

    Topics: Academic Medical Centers; Acute Disease; Aged; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Incidence; Intravitreal Injections; Male; Massachusetts; Postoperative Complications; Ranibizumab; Retinal Diseases; Retrospective Studies; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity

2013
[Introduction to the topic: anti-VEGF therapy in the management of AMD].
    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2008, Volume: 105, Issue:2

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Endophthalmitis; Humans; Injections; Macular Degeneration; Postoperative Care; Ranibizumab; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body

2008
Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
    American journal of ophthalmology, 2008, Volume: 145, Issue:5

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Eye Infections; Humans; Incidence; Injections; Male; Ranibizumab; Retrospective Studies; Risk Factors; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body

2008